ReviewVaccines2016
Influenza and Memory T Cells: How to Awake the Force.
Review in Vaccines, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A Decade in Review: A Systematic Review of Universal Influenza Vaccines in Clinical Trials during the 2010 Decade.Viruses · 2020Pooled it
- Cytokine Profile in Human Peripheral Blood Mononuclear Leukocytes Exposed to Immunoadjuvant and Adjuvant-Free Vaccines Against Influenza.Frontiers in immunology · 2020Trial
- Broadly active intranasal influenza vaccine with a nanocomplex particulate adjuvant targeting mast cells and toll-like receptor 9.Journal of controlled release : official journal of the Controlled Release Society · 2025Article
- Reduced immune response to SARS-CoV-2 infection in the elderly after 6 months.Frontiers in immunology · 2025Article
- A Recombinant Mosaic HAs Influenza Vaccine Elicits Broad-Spectrum Immune Response and Protection of Influenza a Viruses.Vaccines · 2024Article
- Co-Delivery of a Novel Lipidated TLR7/8 Agonist and Hemagglutinin-Based Influenza Antigen Using Silica Nanoparticles Promotes Enhanced Immune Responses.Pharmaceutics · 2024Article
- A mosaic influenza virus-like particles vaccine provides broad humoral and cellular immune responses against influenza A viruses.NPJ vaccines · 2023Article
- Flow cytometry as an integrative method for the evaluation of vaccine immunogenicity: A validation approach.Biochemistry and biophysics reports · 2023Article
- An epitope-optimized human H3N2 influenza vaccine induces broadly protective immunity in mice and ferrets.NPJ vaccines · 2022Article
- Influenza Vaccine: An Engineering Vision from Virological Importance to Production.Biotechnology and bioprocess engineering : BBE · 2022Review
- The role of cell-mediated immunity against influenza and its implications for vaccine evaluation.Frontiers in immunology · 2022Review
- Cytotoxin-Associated Gene A-NegativeFrontiers in microbiology · 2022Article
- Epigraph hemagglutinin vaccine induces broad cross-reactive immunity against swine H3 influenza virus.Nature communications · 2021Article
- TLR7 and RIG-I dual-adjuvant loaded nanoparticles drive broadened and synergistic responses in dendritic cells in vitro and generate unique cellular immune responses in influenza vaccination.Journal of controlled release : official journal of the Controlled Release Society · 2021Article
- Investigating the Interaction between Negative Strand RNA Viruses and Their Hosts for Enhanced Vaccine Development and Production.Vaccines · 2021Review
- Noninvasive Immuno-PET Imaging of CD8Frontiers in immunology · 2021Article
- Immunity and Protective Efficacy of Mannose Conjugated Chitosan-Based Influenza Nanovaccine in Maternal Antibody Positive Pigs.Frontiers in immunology · 2021Article
- Modified Vaccinia Ankara-Vectored Vaccine Expressing Nucleoprotein and Matrix Protein 1 (M1) Activates Mucosal M1-Specific T-Cell Immunity and Tissue-Resident Memory T Cells in Human Nasopharynx-Associated Lymphoid Tissue.The Journal of infectious diseases · 2020Article
- Multi-Epitope Peptide-Based and Vaccinia-Based Universal Influenza Vaccine Candidates Subjected to Clinical Trials.The Malaysian journal of medical sciences : MJMS · 2020Review
- Specific targeting of IL-1β activity to CD8NPJ vaccines · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Annual influenza vaccination is an effective way to prevent human influenza. Current vaccines are mainly focused on eliciting a strain-matched humoral immune response, requiring yearly updates, and do not provide protection for all vaccinated individuals. The past few years, the importance of cellular immunity, and especially memory T cells, in long-lived protection against influenza virus has become clear. To overcome the shortcomings of current influenza vaccines, eliciting both humoral and cellular immunity is imperative. Today, several new vaccines such as infection-permissive and recombinant T cell inducing vaccines, are being developed and show promising results. These vaccines will allow us to stay several steps ahead of the constantly evolving influenza virus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.